Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
P/E ratio for Tempest Therapeutics, Inc. (TPST)
P/E ratio as of 2023: -2.30
According to Tempest Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.30. At the end of 2022 the company had a P/E ratio of -0.36.
P/E ratio history for Tempest Therapeutics, Inc. from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.30 |
| 2022 | -0.36 |
| 2021 | -0.68 |
| 2020 | -0.05 |
| 2019 | -2.07 |
| 2018 | -0.45 |
| 2017 | 0.00 |
| 2016 | -0.60 |
| 2015 | -3.61 |
| 2014 | -20.22 |
| 2013 | -7.13 |
| 2012 | 0.00 |